DE69710390T2 - Pharmazeutische Zusammensetzungen mit Mirtazapin und einem oder mehreren selektiven Serotonin-Aufnahme Inhibitoren - Google Patents

Pharmazeutische Zusammensetzungen mit Mirtazapin und einem oder mehreren selektiven Serotonin-Aufnahme Inhibitoren

Info

Publication number
DE69710390T2
DE69710390T2 DE69710390T DE69710390T DE69710390T2 DE 69710390 T2 DE69710390 T2 DE 69710390T2 DE 69710390 T DE69710390 T DE 69710390T DE 69710390 T DE69710390 T DE 69710390T DE 69710390 T2 DE69710390 T2 DE 69710390T2
Authority
DE
Germany
Prior art keywords
mirtazapine
ssris
fluoxetine
pharmaceutically acceptable
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69710390T
Other languages
German (de)
English (en)
Other versions
DE69710390D1 (de
Inventor
Victor Johannes Nickolson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69710390(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Publication of DE69710390D1 publication Critical patent/DE69710390D1/de
Application granted granted Critical
Publication of DE69710390T2 publication Critical patent/DE69710390T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69710390T 1996-06-19 1997-06-17 Pharmazeutische Zusammensetzungen mit Mirtazapin und einem oder mehreren selektiven Serotonin-Aufnahme Inhibitoren Expired - Fee Related DE69710390T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96201703 1996-06-19

Publications (2)

Publication Number Publication Date
DE69710390D1 DE69710390D1 (de) 2002-03-21
DE69710390T2 true DE69710390T2 (de) 2002-08-14

Family

ID=8224094

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69710390T Expired - Fee Related DE69710390T2 (de) 1996-06-19 1997-06-17 Pharmazeutische Zusammensetzungen mit Mirtazapin und einem oder mehreren selektiven Serotonin-Aufnahme Inhibitoren

Country Status (24)

Country Link
US (1) US5977099A (enExample)
JP (2) JP4925074B2 (enExample)
KR (1) KR100481254B1 (enExample)
CN (1) CN1132581C (enExample)
AR (1) AR007609A1 (enExample)
AT (1) ATE213159T1 (enExample)
AU (1) AU727851B2 (enExample)
BR (1) BR9703624A (enExample)
CA (1) CA2208199C (enExample)
CZ (1) CZ290691B6 (enExample)
DE (1) DE69710390T2 (enExample)
DK (1) DK0813873T3 (enExample)
ES (1) ES2172744T3 (enExample)
HU (1) HU225534B1 (enExample)
ID (1) ID17051A (enExample)
IL (1) IL121076A (enExample)
NO (1) NO313177B1 (enExample)
NZ (1) NZ328113A (enExample)
PL (1) PL188520B1 (enExample)
PT (1) PT813873E (enExample)
RU (1) RU2181287C2 (enExample)
SG (1) SG60073A1 (enExample)
TR (1) TR199700522A2 (enExample)
ZA (1) ZA975335B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US6303595B1 (en) * 1997-11-14 2001-10-16 Akzo Nobel N.V. Use of mirtazapine for treating sleep apneas
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
US6575147B2 (en) * 1999-02-25 2003-06-10 Go-Tec Internal combustion system adapted for use of a dual fuel composition including acetylene
US6545149B2 (en) 1999-04-19 2003-04-08 Teva Pharmaceutical Industries Ltd. Synthesis and crystallization of piperazine ring-containing compounds
EP1178805A4 (en) * 1999-04-19 2004-11-24 Teva Pharma NOVEL SYNTHESIS AND CRYSTALLIZATION OF PIPERAZINE-CONTAINING COMPOUNDS
US6759437B2 (en) * 1999-10-04 2004-07-06 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity including cysteine
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
TWI256309B (en) * 1999-10-13 2006-06-11 Akzo Nobel Nv New formulation of mirtazapine
HUP0204050A3 (en) * 2000-01-19 2004-09-28 Akzo Nobel Nv Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
EP1656937A1 (en) * 2000-02-11 2006-05-17 Akzo Nobel N.V. The use of mirtazapine for the treatment of sleep disorders
WO2002036113A1 (en) * 2000-11-01 2002-05-10 Respiratorius Ab Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
DE60224078T2 (de) * 2001-02-12 2008-12-04 N.V. Organon Verwendung von Mirtazapin zur Verbesserung der Behandlung von Menschen mit starken Depressionen, welche Träger des Gens für Apolipoprotein E4 sind.
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20090311795A1 (en) * 2002-03-21 2009-12-17 Hinz Martin C Bilateral control of functions traditionally regulated by only serotonin or only dopamine
CA2479218A1 (en) * 2002-03-21 2003-10-02 Martin C. Hinz Serotonin and catecholamine system segment optimization technology
US20070293571A1 (en) * 2006-06-08 2007-12-20 Hinz Martin C Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes
AU2003274608A1 (en) * 2002-11-07 2004-06-07 Sunil Sadanand Nadkarni Process for preparation of polymorphic form of sertraline hydrochloride
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
AU2003295235B2 (en) * 2002-12-27 2008-06-19 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
BRPI0407619A (pt) * 2003-02-21 2006-03-01 Martin C Hinz tecnologia de otimização de segmento de sistema serotonina e catecolamina
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
ES2639579T3 (es) 2003-04-29 2017-10-27 Orexigen Therapeutics, Inc. Composiciones para afectar la pérdida de peso que comprende un antagonista opioide y bupropión
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
US7838029B1 (en) 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
ES2426915T3 (es) 2003-09-10 2013-10-25 Brentwood Equities Ltd. Diastereoisómeros de 4-ariloxi-3-hidroxipiperidinas
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
TW200538100A (en) * 2004-04-21 2005-12-01 Akzo Nobel Nv Mirtazapine salts
US20060039866A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
RU2283097C2 (ru) * 2004-11-16 2006-09-10 Эльвира Ивановна Белобородова Способ лечения бронхиальной астмы, сочетанной с эрозивно-язвенными поражениями гастродуоденальной зоны
US20060122127A1 (en) * 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
EP2292269A3 (en) * 2004-11-19 2011-08-10 N.V. Organon Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
JP5180092B2 (ja) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
AR063959A1 (es) 2006-11-09 2009-03-04 Orexigen Therapeutics Inc Formulaciones farmaceuticas en capas
CN101573103A (zh) 2006-11-09 2009-11-04 奥雷西根治疗公司 用于施用重量减轻药物的单位剂量包装和方法
EP2167096A4 (en) * 2007-06-13 2010-07-14 Cypress Bioscience Inc IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM
CN101332193B (zh) * 2007-06-29 2012-12-12 杭州民生药业有限公司 一种马来酸氟伏沙明药物组合物的制备方法
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US8768578B2 (en) 2009-06-09 2014-07-01 Sumitomo Heavy Industries, Ltd. Hybrid excavator and method of controlling hybrid excavator
KR101414012B1 (ko) * 2009-11-13 2014-07-01 주식회사 녹십자 아릴피페라진-함유 퓨린 유도체 및 그의 용도
KR20120124423A (ko) 2010-01-11 2012-11-13 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
CN102000334B (zh) * 2010-10-15 2012-02-22 北京大学 用于治疗抑郁症的复方制剂
RU2475235C2 (ru) * 2011-03-15 2013-02-20 Общество с ограниченной ответственностью "ЭР ЭНД ДИ ФАРМА" Фармацевтическая композиция для профилактики и лечения депрессивных состояний
JOP20120083B1 (ar) * 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
RS67076B1 (sr) 2012-06-06 2025-08-29 Nalpropion Pharmaceuticals Llc Kompozicija za upotrebu u postupku lečenja prekomerne težine i gojaznosti kod pacijenata sa visokim kardiovaskularnim rizikom

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) * 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
AU8770282A (en) * 1981-08-27 1983-03-03 Shaun R. Coughlin Composition for the treatment of atherosclerosis
US4940585A (en) * 1989-02-17 1990-07-10 Hapworth William E Method for the treatment of nicotine withdrawal syndrome
EP0431663B1 (en) * 1989-12-06 1994-01-12 Akzo Nobel N.V. Stabilized solutions of psychotropic agents
US5208261A (en) * 1989-12-06 1993-05-04 Akzo N.V. Stabilized solutions of psychotropic agents
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
TW587938B (en) * 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
WO1999017803A1 (en) * 1997-10-03 1999-04-15 Cary Medical Corporation Compositon for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug

Also Published As

Publication number Publication date
CZ187097A3 (cs) 1998-01-14
AU2612997A (en) 1998-01-08
BR9703624A (pt) 1998-09-01
ATE213159T1 (de) 2002-02-15
NO313177B1 (no) 2002-08-26
JP4925074B2 (ja) 2012-04-25
NZ328113A (en) 1999-09-29
TR199700522A3 (tr) 1998-01-21
CZ290691B6 (cs) 2002-09-11
HU9701068D0 (en) 1997-08-28
MX9704579A (es) 1998-07-31
US5977099A (en) 1999-11-02
ZA975335B (en) 1998-01-26
PL188520B1 (pl) 2005-02-28
ES2172744T3 (es) 2002-10-01
TR199700522A2 (xx) 1998-01-21
RU2181287C2 (ru) 2002-04-20
AU727851B2 (en) 2001-01-04
HU225534B1 (en) 2007-02-28
IL121076A0 (en) 1997-11-20
NO972816D0 (no) 1997-06-18
HK1006081A1 (en) 1999-02-12
CN1132581C (zh) 2003-12-31
HUP9701068A2 (hu) 1998-08-28
CA2208199C (en) 2006-10-24
PT813873E (pt) 2002-06-28
AR007609A1 (es) 1999-11-10
DE69710390D1 (de) 2002-03-21
PL320628A1 (en) 1997-12-22
IL121076A (en) 2000-10-31
CN1173330A (zh) 1998-02-18
JP2009137970A (ja) 2009-06-25
HUP9701068A3 (en) 2000-07-28
JPH1067663A (ja) 1998-03-10
KR980000447A (ko) 1998-03-30
NO972816L (no) 1997-12-22
CA2208199A1 (en) 1997-12-19
KR100481254B1 (ko) 2005-09-12
DK0813873T3 (da) 2002-05-27
ID17051A (id) 1997-12-04
SG60073A1 (en) 1999-02-22

Similar Documents

Publication Publication Date Title
DE69710390T2 (de) Pharmazeutische Zusammensetzungen mit Mirtazapin und einem oder mehreren selektiven Serotonin-Aufnahme Inhibitoren
DE60103556T3 (de) Zusammensetzungen zur behandlung von fettleibigkeit, welche antagonisten der cb1-rezeptoren und sibutramine enthalten
DE69434872T2 (de) Neue Behandlungsmethoden durch Verwendung von Phenethylderivaten
DE3688296T2 (de) Arzneimittel zur behandlung von erbrechen.
DE60009697T2 (de) Verwendung von 1-[4-(5-cyanoindol-3yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazin und dessen physiologisch akzeptablen salzen zur behandlung von bipolaren krankheiten und manie
DE69034149T2 (de) Verwendung von Sertralin zur Behandlung von posttraumatischen Stresserkrankungen
DE60218193T2 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
DE19858789A1 (de) Kombination von Cerivastatin und Fibraten
EP0521388B1 (de) Verfahren zur Herstellung einer pharmazeutischen Zubereitung mit wenigstens zwei verschiedenen Wirkstoffen und Verwendung einer solchen Zubereitung
DE60122015T2 (de) Behandlung affektiver störungen durch kombinierte wirkung eines nikotinischen rezeptoragonisten und einer monoaminergischen substanz
NZ504656A (en) Substituted aminomethyl-chromans are used for the regenerative treatment of neurological conditions which are the sequelae of damage due to surgical intervention, exposure to toxic agents, infections, tumours, and other diseases and conditions
DE2513940A1 (de) Pharmazeutische zubereitung
DE69129750T2 (de) Neue medizinische anwendung eines gewissen indolderivates und dieses enthaltende pharmazeutische zubereitung
EP0035597B1 (de) Pharmazeutische Zubereitungen
DE60313886T2 (de) Zusammensetzung von einem PPAR-alpha Agonisten und Metformin zur Behandlung von Obesitas
DE69431986T2 (de) Verwendung von granisetron zur behandlung von postoperativer übelkeit und erbrechen
EP1461042B1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
DE60125062T2 (de) Quetiapin zur Behandlung der Dyskinesie in nicht-psychotischen Patienten
DE69004529T2 (de) Verwendung von Sertralin zur Behandlung von Abhängigkeiten von chemischen Stoffen.
DE2823268C2 (enExample)
WO2001026659A1 (de) Arzneimittel zur behandlung von neuropathien
DE2128730A1 (de) Mittel zur Kompensierung eines Dopaminmangels im Gehirn
DE2831728C2 (de) Arzneimittel zur Behandlung von Kopfschmerzen
EP1307195A2 (de) Cilansetron enthaltende arzneimittel zur behandlung nicht-obstipativer männlicher ibs-patienten
DE2823267C2 (enExample)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: N.V. ORGANON, OSS, NL

8339 Ceased/non-payment of the annual fee